Edit Metric

Company
Value
Source
Source URL
Notes
		Cancel

Edit | History

Details

Company:
Value :
Source:
Source URL:
Notes:

Feedback | FAQ

Get involved

Companies | Concepts | Contributors

PDL BioPharma (PDLI)

Stock (Drug Manufacturers - Other Industry, Pharma & Healthcare Industry)

Revenues below consenus, job reduction PDL BioPharma reported Q4 revenue of $49.8 million and non-GAAP EPS of $0.04, which includes revenue from discontinued operations, below consensus of $110.8 million and $0.18. 260 jobs are to be cut. Management also indicated that they failed to obtain any firm offers for the sale of the company. PDL BioPharma plans to sell its key assets PDL BioPharma announced that it is planning to sell its key assets, and if possible the entire business. The company is seeking strategic alternatives. Wachovia Securities expects that the company will be able to sell its drug and drug pipeline. Further, Wachovia feels that this business is worth $12-13 per share and the company can expect a premium of 10-20 percent. This news and a rating upgrade from ‘Market Perform’ to ‘Outperform’ resulted in an increase in the stock price of PDL BioPharma. PDL BioPharma to sell its commercial assets PDL BioPharma plans to sell its commercial assets (such as Cardene and IV Busulfex products) and reduce its workforce. Further, the company will also terminate Nuvion phase 3 program in ulcerative colitis, citing poor safety profile and insufficient efficacy as the reason.

The Shelf

Worried about pump and dump?

We review changes
for stock spam

» read more

Want to make Wikinvest better?

We need your help,
contribute today

» learn how

Do you write software?

We are recruiting
the best engineers

» view jobs

Like Wikinvest?

Spread the word —
Tell your friends!

» spread the word

Wikinvest © 2006, 2007, 2008. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.